A few weeks ago, I published a post in this blog, Drug Safety Progressives - The Rise of the Pharmacovigilante. I was blown away by the positive response and resulting discussions. I even received a few requests for the t-shirt shown in the picture, but I’m sorry to say that our business model is based on software-as-a-service, not retail. But I digress… back to the Pharmacovigilantes…
Recently, Advera Health released a comparative safety report of the HER2+ Antagonists. In this drug review, we analyzed FDA Adverse Event Reporting System (FAERS) and clinical trial data to better understand how the drugs in this class stacked up.
The United States is a polarized place right now. Democrats vs. Republicans. Liberals vs. Conservatives. President Trump vs. the world. The divide runs deep and battle lines have been drawn. And while there is no escaping this highly publicized political chasm, there is another fight being played out in the shadows… The Drug Safety Progressives vs. the Drug Safety Conservatives.
I was at the DIA Pharmacovigilance and Risk Management conference last week, fittingly taking place in Washington D.C right after the inauguration and the women’s march. The division was obvious.
We were very excited this Monday to announce a new partnership with APCER Life Sciences, a global provider of safety, medical, regulatory, and technology services to the pharmaceutical industry. Working with the dedicated professionals at APCER will enable us to expand our reach into the safety and pharmacovigilance departments at pharmaceutical companies globally.
This week we launched Evidex Alerts, a new feature that provides our clients with real-time updates on the latest impactful drug safety news. This is a project that our development and analyst teams have worked on diligently for the last three months, and I am excited to announce that it became a reality this week.
On this past Sunday’s 60 Minutes, astronomer Mike Brown made a bold prediction – that within three years the scientific community would identity a new, large 9th planet located in the outermost area of our solar system. Even more astonishing was how certain he was about that prediction, “I would say at this point, I am certain….that’s a rare thing to say – for a prediction for a scientist. And I’m willing to say it.” Mike Brown has some credibility in this area, as he’s the guy who figured out that Pluto wasn’t a planet after all. Maybe it’s his own guilt over breaking every school-kid’s heart that’s driving his prediction, but both his prediction and his certainty really fascinated me. If you haven’t watched the report, I’d urge you to do so (link is here).
Topics: Drug Safety
In November 2016, I was honored to be asked to join the Board of Directors of the Foundation for Sarcoidosis Research (FSR). The foundation began in 1999 as a grassroots organization, and now has expanded their efforts and impact to become the leader in supporting sarcoidosis research. I'm looking forward to using my experiences both as a sarcoidosis patient and in drug safety to contribute to the mission. Please visit www.stopsarcoidosis.org for more information.
I originally wrote the post below for the FSR blog. The original can be seen here.
As 2016 winds down, am I the only one who feels exhausted?
Between pharma-bro inspired drug pricing madness, a political season that felt like a Bravo reality TV show, and Leicester City robbing my beloved Tottenham Hotspur of their first shot at a Premiere League championship in a very long time, I think John Oliver summed up this year best in this video.